Freeline_Logo_Red_RGB.jpg
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2022 17:30 ET | Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022 07:00 ET | Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
Freeline_Logo_Red_RGB.jpg
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022 16:01 ET | Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
Freeline_Logo_Red_RGB.jpg
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
July 21, 2022 07:00 ET | Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Freeline_Logo_Red_RGB.jpg
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET | Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
Freeline_Logo_Red_RGB.jpg
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET | Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Freeline_Logo_Red_RGB.jpg
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:02 ET | Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022 16:01 ET | Freeline Therapeutics
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on March 31, 2022, the Company granted its newly hired...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Full Year 2021 Financial Results and Business Highlights
March 31, 2022 16:01 ET | Freeline Therapeutics
Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Companythrough key data readouts across...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
March 24, 2022 07:00 ET | Freeline Therapeutics
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline...